

[REDACTED]

**From:** Nasr, Samia  
**Sent:** Monday, September 14, 2009 3:34 PM  
**To:** Anderson, Kathleen R; [REDACTED]  
**Cc:** Nasr, Samia  
**Subject:** FW: Erythromycin ointment update  
**Attachments:** NECC FLYER - Erythromycin pdf; FAQs erythromycin ophthalmic doc

Look at the highlighted part concerning NECC and how they compound the ointment (I think) without a prescription

*Samia M. Nasr, R.Ph., M.S.  
Team Leader  
Division of New Drugs and Labeling Compliance  
Office of Compliance, CDER, FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
Bldg 51, room 5370*

[REDACTED]

e-mail address [REDACTED]

**From:** [REDACTED]  
**Sent:** Monday, September 14, 2009 3:26 PM  
**To:** Nasr, Samia  
**Subject:** FW: Erythromycin ointment update

Samia,

Hope all is well. Not sure if you saw this flyer but I was wondering how NECC can package and sell erythromycin ointment legally.

Best regards,

[REDACTED]

Please note new email address [REDACTED]

11/29/2012

# Erythromycin

## Ophthalmic Ointment

- 0.5% Erythromycin Ointment
- Provides antibiotic coverage
- Tamper-resistant
- Beyond Use Date (BUD)
- Storage: 2-8°C (36-46°F)
- Linear

ERYTHROMYCIN 0.5% 1 GM  
Sterile ophthalmic ointment  
Exp. 02/22/2010 Ophthalmic Use Only  
Lot# 08752008-0-80 Topical Use Only

All forms of barrier isolation are required for all patients with  
USP 797 and USP 800 compliance.  
All eye care components must be used in a clean environment  
extensively decontaminated and disinfected.  
Medications are placed in a barrier isolator (BIO) or a clean room  
(barrier isolator).  
Medications are compounded in a clean room or barrier isolator.

Please call today to discuss barrier isolation needs.



697 Waverly Street, Framingham, MA 01702



[www.neccpx.com](http://www.neccpx.com)